Takeda Announces Mutual Termination of Amylin / Takeda Worldwide Agreement to Co-Develop and Commercialize Compounds for Obesity<4502.T>

Mon Dec 24, 2012 6:00pm EST

* Reuters is not responsible for the content in this press release.

For best results when printing this announcement, please click on the link
below:

http://pdf.reuters.com/pdfnews/pdfnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20121224:nPnNY34251


OSAKA, Japan  and  DEERFIELD, Ill.,  Dec. 24, 2012  /PRNewswire/ -- Takeda
Pharmaceutical Company Limited (TSE: 4502) today announced that it has mutually
terminated its worldwide agreement with Amylin Pharmaceuticals, Inc., originally
signed in  October 2009, to co-develop and commercialize compounds for obesity. 


The companies announced in  August 2011  their decision to discontinue the
development of pramlintide/metreleptin, an investigational combination therapy
for the treatment of obesity. That joint decision was based on a commercial
reassessment of the pramlintide/metreleptin program, which had been in Phase 2
development as a twice-a-day injection formulation. The companies have since
determined to formally terminate the partnership at this time. Having greatly
benefited from the Amylin team's collective experience and scientific expertise,
Takeda will continue to enhance its R&D activities in the area of obesity as
well as its other core therapeutic areas to meet the needs of patients.  

Takeda's consolidated financial statement for the fiscal 2012 will not be
impacted by the termination of this partnership.

About Takeda Pharmaceutical Company Limited
Located in  Osaka, Japan, Takeda is a research-based global company with its
main focus on pharmaceuticals. As the largest pharmaceutical company in  Japan 
and one of the global leaders of the industry, Takeda is committed to strive
towards better health for patients worldwide through leading innovation in
medicine. Additional information about Takeda is available through its corporate
website,  www.takeda.com.  

This press release contains forward-looking statements. Forward-looking
statements include statements regarding Takeda's plans, outlook, strategies, or
results for the future, and other statements that are not descriptions of
historical facts. Forward-looking statements may be identified by the use of
forward-looking words such as "may," "believe," "will," "expect," "project,"
"estimate," "should," "anticipate," "plan," "assume," "continue," "seek," "pro
forma," "potential," "target," "forecast," "guidance," "outlook" or "intend" or
other similar words or expressions of the negative thereof. Forward-looking
statements are based on estimates and assumptions made by management that are
believed to be reasonable, though they are inherently uncertain and difficult to
predict. Investors are cautioned not to unduly rely on such forward-looking
statements.

Forward-looking statements involve risks and uncertainties that could cause
actual results or experience to differ materially from that expressed or implied
by the forward-looking statements. Some of these risks and uncertainties
include, but are not limited to, (1) the economic circumstances surrounding
Takeda's business, including general economic conditions in  Japan,  the United
States  and worldwide; (2) competitive pressures and developments; (3)
applicable laws and regulations; (4) the success or failure of product
development programs; (5) actions of regulatory authorities and the timing
thereof; (6) changes in exchange rates; (7) claims or concerns regarding the
safety or efficacy of marketed products or product candidates in development;
and (8) integration activities with acquired companies.

The forward-looking statements contained in this press release speak only as of
the date of this press release, and Takeda undertakes no obligation to revise or
update any forward-looking statements to reflect new information, future events
or circumstances after the date of the forward-looking statement. If Takeda does
update or correct one or more of these statements, investors and others should
not conclude that Takeda will make additional updates or corrections.

SOURCE  Takeda Pharmaceutical Company Limited


Corporate Communications, Takeda (Japan) Corporate Communications,
+81-3-3278-2037; Takeda (USA) Corporate Communications - Julia Ellwanger,
+1-224-612-0256, julia.ellwanger@takeda.com
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.